Binds Lymphocytic Or Lymphocytic-like Cell Or Component Or Product Thereof (e.g., B Cell, B-lineage Bone Marrow Cell, Null Cell, Natural Killer Cell, B-lymphoblastoid Cell, B-lineage Acute Lymphoblastic Leukemia Cell, B-lymphocytic Cell-surface Antigen, Etc.) Patents (Class 530/388.73)
-
Patent number: 6592868Abstract: This invention provides methods of treating autoimmune diseases, including those selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopenia purpura, hemolytic anemia and diabetes mellitus with 5C8-specific antibodies.Type: GrantFiled: June 7, 1995Date of Patent: July 15, 2003Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Patent number: 6579688Abstract: Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be used for various analytical or other methods.Type: GrantFiled: December 14, 2000Date of Patent: June 17, 2003Assignee: Biostar, Inc.Inventors: Jeffrey W. Steaffens, Laura Panzarella
-
Patent number: 6576236Abstract: When stimulated through the T cell receptor(TCR)/CD3 complex without requisite costimulation through the CD28/B7 interaction, T cells enter a state of antigen specific unresponsiveness or anergy. This invention is based, at least in part, on the discovery that signaling though a common cytokine receptor &ggr; chain (e.g., interleukin-2 receptor, interleukin-4 receptor, interleukin-7 receptor) prevents the induction of T cell anergy. This &ggr; chain has been found to be associated with a JAK kinase having a molecular weight of about 116 kD (as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis) and signaling through the &ggr; chain induces phosphorylation of the JAK kinase. Accordingly, methods for stimulating or inhibiting proliferation by a T cell which expresses a cytokine receptor &ggr; chain are disclosed.Type: GrantFiled: July 1, 1994Date of Patent: June 10, 2003Assignee: Dana Farber Cancer InstituteInventors: Vassiliki A. Boussiotis, Lee M. Nadler
-
Patent number: 6565827Abstract: Methods for the treatment of lymphoma by administration of a B cell-specific antibody are described. The invention encompasses providing to a patient both unlabeled antibodies and antibodies labeled with a radioisotope. A principal advantage of the method is that tumor responses can be obtained in a radiometric dose range that does not require hematopoietic stem cell replacement as an adjunct therapy.Type: GrantFiled: August 7, 2001Date of Patent: May 20, 2003Assignees: Coulter Pharmaceutical, Inc., The Regents of the University of MichiganInventors: Mark S. Kaminski, Gregory M. Butchko, Stephan D. Glenn, Richard L. Wahl
-
Patent number: 6541611Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.Type: GrantFiled: June 14, 2000Date of Patent: April 1, 2003Assignee: Universite Catholique de LouvainInventors: Hervé Bazin, Dominique Latinne, Pierre Gianello
-
Patent number: 6538110Abstract: The invention concerns an antibody composition which inhibits the binding of interleukin 2 to its high affinity receptor and contains (1) monoclonal antibodies against the &agr; chain of the interleukin 2 receptor and (2) monoclonal antibodies against the &bgr; chain of the interleukin 2 receptor, as well as a pharmaceutical agent which contains the antibody composition according to the present invention.Type: GrantFiled: March 10, 1993Date of Patent: March 25, 2003Assignee: Roche DiagnosticsInventors: Ulrich Weidle, Eberhard Russmann, Klaus-Peter Hirth, Tiberiu Diamantstein, Brigitte Kaluza
-
Patent number: 6534057Abstract: Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV) infection into a nonserious disease through the infusion of monoclonal antibodies directed against particular antigens on anti-self, anti-CD4 cytotoxic T-lymphocytes. The monoclonal antibodies are primarily directed against the alpha or beta chain of LFA-1.Type: GrantFiled: September 30, 1997Date of Patent: March 18, 2003Inventor: Allen D. Allen
-
Patent number: 6528625Abstract: The present invention relates to an antibody or functional portion thereof which binds to a mammalian (e.g., human) chemokine receptor 5 protein (CKR-5 or CCR5) or portion of the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR5 with a ligand thereof. Another aspect of the invention relates to a method of inhibiting HIV infection of a cell which expresses a mammalian CCR5 or portion thereof using the antibodies described herein. Also encompassed by the present invention are methods of treating or preventing HIV in a patient.Type: GrantFiled: July 11, 1997Date of Patent: March 4, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Lijun Wu, Charles R. Mackay
-
Patent number: 6525180Abstract: Purified genes encoding a T cell surface antigen from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this antigen are provided. Methods of using said reagents and diagnostic kits are also provided.Type: GrantFiled: September 27, 2000Date of Patent: February 25, 2003Assignee: Schering CorporationInventors: Daniel M. Gorman, Jeanine D. Mattson
-
Patent number: 6521230Abstract: Monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection, paticularly in combination with other antibodies to activated T-cells, for example CD7 antibodies.Type: GrantFiled: March 14, 1991Date of Patent: February 18, 2003Assignees: Novartis AG, University College LondonInventors: Peter Lloyd Amlot, Arne Nalpon Akbar, Günther Heinrich, Salvatore Cammisuli
-
Patent number: 6511665Abstract: The present invention provides monoclonal antibodies and binding proteins which specifically bind to the IL-1 receptor. Also provided are methods for detecting IL-1 receptors on cells, and for detecting soluble IL-1 receptors in serum.Type: GrantFiled: May 30, 1995Date of Patent: January 28, 2003Assignee: Immunex CorporationInventors: Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
-
Patent number: 6506383Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.Type: GrantFiled: June 14, 1999Date of Patent: January 14, 2003Assignee: IDEC Pharmaceuticals CorporationInventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
-
Patent number: 6503509Abstract: Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.Type: GrantFiled: February 25, 2000Date of Patent: January 7, 2003Assignee: National Jewish Medical & Research CenterInventors: Barbara J. Vilen, John C. Cambier
-
Publication number: 20020187135Abstract: Methods for inducing antigen-specific T cell tolerance are disclosed. The methods involve contacting a T cell with: 1) a cell which presents antigen to the T cell, wherein a ligand on the cell interacts with a receptor on the surface of the T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor on the surface of the T cell which inhibits interaction of the ligand on the antigen presenting cell with the receptor on the T cell. In a preferred embodiment, the cell which presents antigen to the T cell is a B cell and the receptor on the surface of the T cell which mediates contact-dependent helper effector function is gp39. Preferably, the antagonist is an anti-gp39 antibody or a soluble gp39 ligand (e.g., soluble CD40). The methods of the invention can be used to induce T cell tolerance to a soluble antigen or to an allogeneic cell.Type: ApplicationFiled: October 1, 1998Publication date: December 12, 2002Inventors: RANDOLPH J. NOELLE, TERESA M. FOY, FIONA H. DURIE
-
Patent number: 6491918Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.Type: GrantFiled: October 28, 1999Date of Patent: December 10, 2002Assignee: StemCell Technologies Inc.Inventors: Terry Thomas, Peter Lansdorp
-
Publication number: 20020176855Abstract: The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant rejection, inflammatory disorders and infectious diseases by administering humanized anti-B7-2 and/or anti-B7-1 antibodies.Type: ApplicationFiled: February 12, 1999Publication date: November 28, 2002Inventors: MAN SUNG CO, MAXIMILIANO VASQUEZ, BEATRIZ CARRENO, ABBIE CHERYL CELNIKER, MARY COLLINS, SAMUEL GOLDMAN, GARY S. GRAY, ANDREA KNIGHT, DENISE O'HARA, BONITA RUP, GEERTRUIDA M. VELDMAN
-
Patent number: 6485970Abstract: The present invention relates generally to immunointeractive molecules and their use inter alia in the detection and/or purification of T-cell antigen binding molecules (TABMs). The ability to determine the presence and levels of particular TABMs provides a useful diagnostic procedures for a variety of disease conditions.Type: GrantFiled: May 10, 2000Date of Patent: November 26, 2002Inventors: Robert E. Cone, George M. Georgiou, Colin H. Little
-
Patent number: 6482926Abstract: The present invention relates to antibody composition that are useful in preparing enriched cell preparations such as human hematopoietic progenitor cells and stem cells and non-hematopoietic tumor cells. The invention also relates to kits for carrying out the processes and to the cell preparations prepared by the processes.Type: GrantFiled: March 22, 2000Date of Patent: November 19, 2002Assignee: StemCell Technologies Inc.Inventors: Terry Thomas, Peter Lansdorp
-
Patent number: 6479247Abstract: Isolated antibody or preparation of antibodies comprising an antigen-binding domain wherein the antigen is present on activated dendritic cells and wherein the antibody does not interact with CMRF-44 antigen or CD83 antigen.Type: GrantFiled: April 29, 1999Date of Patent: November 12, 2002Assignee: The Corporation of the Trustees of the Order of the Sisters of Mercy in QueenslandInventor: Derek N. J. Hart
-
Patent number: 6458934Abstract: The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.Type: GrantFiled: November 12, 1999Date of Patent: October 1, 2002Assignee: LG Chemical LimitedInventors: Hyo Jeong Hong, Sung Sup Park, Young Jun Kang, Chang-Yuil Kang, Sung Kwan Yoon
-
Patent number: 6455044Abstract: This invention provides for an isolated protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. This invention also provides for an isolated protein having substantially the same biological activity as the aforementioned isolated protein. In addition, this invention provides for a pharmaceutical composition comprising the isolated protein and a pharmaceutically acceptable carrier.Type: GrantFiled: April 14, 1999Date of Patent: September 24, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Patent number: 6451310Abstract: This invention provides a method of inhibiting an allergic response in a subject by inhibiting T cell activation of B cells, wherein said method comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5C8 produced by the hybridoma having ATCC Accession No. HB 10916.Type: GrantFiled: June 7, 1995Date of Patent: September 17, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Publication number: 20020122797Abstract: The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.Type: ApplicationFiled: October 15, 1997Publication date: September 5, 2002Applicant: Genentech, Inc.Inventor: KYUNG J. KIM
-
Patent number: 6440418Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases; and an immunosuppressant during transplantation of heterologous cells, tissues or organs, cell therapy, and gene therapy.Type: GrantFiled: September 8, 1997Date of Patent: August 27, 2002Assignee: IDEC Pharmaceuticals CorporationInventors: Amelia Black, Nabil Hanna, Eduardo A. Padlan, Roland A. Newman
-
Methods of inhibiting locomotor damage following spinal cord injury with &agr; D-specific antibodies
Patent number: 6432404Abstract: Methods to treat spinal cord injury using &agr;d monoclonal antibodies are disclosed.Type: GrantFiled: October 13, 2000Date of Patent: August 13, 2002Assignee: ICOS CorporationInventors: W. Michael Gallatin, Monica Van der Vieren -
Patent number: 6419928Abstract: Monoclonal antibodies to transforming growth factor beta (TGF-B) are prepared from hybrid cell lines by immunizing with TGF-B2. The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF-B monoclonal antibody are also disclosed.Type: GrantFiled: March 21, 2000Date of Patent: July 16, 2002Assignee: Genzyme CorporationInventors: James R. Dasch, Doran R. Pace, III, Wendy O. Waegell
-
Patent number: 6413514Abstract: A method for the treatment of T cell mediated disorders is described. The method involves administering to a subject a therapeutically effective amount of an anti-human CD40 antibody. Disease states suitable for treatment with this method include graft versus host disease and transplant rejection and auto immune disease such as type I diabetes, psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, and myesthenia gravis.Type: GrantFiled: December 17, 1999Date of Patent: July 2, 2002Assignee: Bristol-Myers Squibb CompanyInventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath
-
Patent number: 6406696Abstract: Disclosed are immunopotentiating agents, and vaccines thereof, which enhance and/or otherwise modify immune responses, and method for their preparation and use in vivo. Immunopotentiating agents can be single agents that act directly, adjuvants added concurrently with the agents, or heteroconjugates wherein the immunopotentiating agent is chemically coupled to the compound against which an immune response is desired. Examples of immunopotentiating agents include monoclonal antibodies, such as anti-CD3, anti-CD2) and anti-CD5 antibodies, and proteins derived from microorganisms (e.g., enterotoxins) which activate T cells. The compounds against which an immune response can be generated, which may be the second component in a heteroconjugate, include compound from abnormal or diseased tissues such as tumors, or infectious agents, such as viruses, bacteria, fungi, protozoal or metozoal parasites, and can be obtained by natural or recombinant means.Type: GrantFiled: June 2, 1995Date of Patent: June 18, 2002Assignee: Tolerance Therapeutics, Inc.Inventor: Jeffery A. Bluestone
-
Methods for inhibiting the rejection of a transplant organ in a subject with 5C8-specific antibodies
Patent number: 6403091Abstract: This invention provides for a method for inhibiting rejection of a transplant organ in a subject which comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. The present invention further provides for a method for inhibiting rejection of a transplant organ in a subject, which comprises administering to the subject a pharmaceutical composition comprising a monoclonal antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession No. HB 10916. In one embodiment of the invention, the transplant organ is a heart, a kidney or a liver. In another embodiment, the monoclonal antibody is 5c8 produced by the hybridoma having ATCC Accession No. HB 10916.Type: GrantFiled: June 7, 1995Date of Patent: June 11, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin -
Patent number: 6399061Abstract: Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.Type: GrantFiled: June 7, 1995Date of Patent: June 4, 2002Assignee: IDEC Pharmaceutical CorporationInventors: Darrell R. Anderson, Nabil Hanna, Roland A. Newman, Mitchell E. Reff, William H. Rastetter
-
Publication number: 20020062008Abstract: Methods to inhibit inflammation and macrophage infiltration following spinal cord injury are disclosed along with methods to modulate TNF&agr; release from cells expressing &agr;d are disclosed.Type: ApplicationFiled: July 8, 1999Publication date: May 23, 2002Inventors: W. MICHAEL GALLATIN, MONICA VAN DER VIEREN
-
Patent number: 6383487Abstract: Novel monoclonal antibodies to the CD25 antigen are characterized by the amino acid sequence of their hypervariable regions. Initially produced in murine form, they may be converted to chimeric or humanized forms, immunoconjugates or antibody fragments (generally described as binding molecules). The products are useful for the prophylaxis or treatment of transplant rejection, paticularly in combination with other antibodies to activated T-cells, for example CD7 antibodies.Type: GrantFiled: June 6, 1995Date of Patent: May 7, 2002Assignees: Novartis AG, University College LondonInventors: Peter Lloyd Amlot, Arne Nalpon Akbar, Günther Heinrich, Salvatore Cammisuli
-
Patent number: 6384198Abstract: An anti-CD2 monoclonal antibody according to the present invention can be: (1) a chimeric nonclonal antibody CD2 SFv-Ig produced by expression of the construct cloned in recombinant Escherichia coli culture ATCC No. 69277; (2) a monoclonal antibody having complementarity-determining regions identical with those of CD2 SFv-Ig; or (3) a monoclonal antibody competing with CD2 SFv-Ig for binding to CD2 antigen at least about 80% as effectively on a molar basis as CD2 SFv-Ig. Anti-CD2 monoclonal antibodies according to the present invention, as well as other antibodies that can modulate the interactions between T lymphocytes and monocytes, can be used to inhibit the production of HIV-1 by HIV-1-infected T cells in HIV-1-infected patients. In another use, T cells treated in vitro can be reinfused into AIDS patients to increase the proportion of functional non-HIV-1-producing T cells in the patient.Type: GrantFiled: May 31, 1995Date of Patent: May 7, 2002Assignee: Bristol-Myers Sqibb CompanyInventors: Michael L Diegel, Peter S Linsley, Lisa K Gilliland, Patricia A Moran, Joyce M Zarling, Jeffrey A Ledbetter
-
Patent number: 6379668Abstract: A method for the prevention or reversal of transplant rejection, or for therapy for autoimmune diseases, is provided comprising administering compounds such as monoclonal antibodies, that bind specifically to one or more preselected CD45R leukocyte antigens.Type: GrantFiled: June 17, 1999Date of Patent: April 30, 2002Assignees: Research Corporation Technologies, Inc., Alimmune, LLCInventors: Andrew I. Lazarovits, Sibrand Poppema
-
Publication number: 20020048578Abstract: This invention relates to an antibody which is a modified version of a therapeutic antibody with affinity for a cell-surface antigen, said antibody having reduced affinity for the antigen compared with the therapeutic antibody as a result of a modification or modifications to the antibody molecule, wherein the antibody is capable of inducing immunological tolerance to the therapeutic antibody. The invention further relates to a method of inducing immunological tolerance to a therapeutic antibody comprising administering to a patient an antibody which is a modified version of the therapeutic antibody and which has reduced affinity for the antigen as compared with the therapeutic antibody.Type: ApplicationFiled: August 19, 1998Publication date: April 25, 2002Inventors: HERMAN WALDMANN, LISA K GILLILAND, MASAHIDE TONE, MARK R FREWIN, LOUISE WALSH
-
Patent number: 6375950Abstract: Methods for inducing T cell tolerance to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.Type: GrantFiled: January 5, 1999Date of Patent: April 23, 2002Assignees: University of Massachusetts Medical Center, Trustees of Dartmouth CollegeInventors: Randolph J. Noelle, Fiona H. Durie
-
Publication number: 20020034509Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: ApplicationFiled: October 2, 2001Publication date: March 21, 2002Inventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
-
Publication number: 20020034507Abstract: A novel inhibitor of lymphocyte activation is provided.Type: ApplicationFiled: January 17, 2001Publication date: March 21, 2002Inventor: Yasuo Koishihara
-
Patent number: 6346248Abstract: A method for treating autoimmune diseases comprising administering to a patient in need of such treatment a therapeutically effective amount of an immunotoxin comprising an anti-human CD86 monoclonal antibody IG10H6D10 as deposited in the ECACC collection under No. 95060210 or a humanized antibody, a single-chain antibody or fragments and specificity of said monoclonal antibody, coupled to a toxin or active fragments thereof wherein the binding of the immunotoxin to CD86 results in the killing of the CD86 expressing cell.Type: GrantFiled: August 12, 1999Date of Patent: February 12, 2002Assignee: Innogenetics N.V.Inventors: Mark De Boer, G. C. De Gast
-
Patent number: 6340459Abstract: Activation of cells bearing CD40 on their cell surface by CD40 ligand is inhibited by contacting the cells with an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Activation of cells bearing CD40 on their surface by CD40 ligand in a subject is inhibited by administering to the subject an agent capable of inhibiting interaction between CD40 ligand and the cells, in an amount effective to inhibit activation of the cells. Reperfusion injury, in an non-transplant recipient, is a condition associated with CD40 ligand-induced activation of CD40-bearing cells. Therefore, reperfusion injury can be treated by the administration of anti-human CD40L monoclonal antibodies, such as those described herein (e.g. 5c8 mAb).Type: GrantFiled: April 22, 1996Date of Patent: January 22, 2002Assignee: The Trustees of Columbia University in the City of New YorkInventors: Michael J. Yellin, Seth Lederman, Leonard Chess
-
Patent number: 6340569Abstract: Disclosed herein are hybridomas, antibodies produced thereby, antigens, and cells identified or isolated therewith. The dendritic like cells preferably have dendritic morphology and B cell phenotype. Methods of utilizing the hybridomas, antibodies, antigens, and cells are also discussed herein.Type: GrantFiled: November 12, 1998Date of Patent: January 22, 2002Assignee: University of PittsburghInventors: Edward D. Ball, Rui-Kun Zhong
-
Patent number: 6331615Abstract: The present invention provides for an isolated nucleic acid molecule encoding a light chain protein of an antibody, wherein the antibody binds specifically to a protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession Number HB 10916. The invention also provides for an isolated nucleic acid molecule encoding a heavy chain protein of an antibody, wherein the antibody binds specifically to a protein specifically recognized by monoclonal antibody 5c8 produced by the hybridoma having ATCC Accession Number HB 10916. The present invention also provides for a gene transfer vector comprising a nucleic acid molecule, a host vector system comprising the gene transfer vector, and a composition comprising a nucleic acid molecule.Type: GrantFiled: April 7, 1999Date of Patent: December 18, 2001Assignee: The Trustees of Columbia University in the City of New YorkInventors: Seth Lederman, Leonard Chess, Michael J. Yellin
-
Patent number: 6328964Abstract: Method for the treatment of multiple sclerosis and other T cell mediated autoimmune disorders is described. The method involves administering to a subject a therapeutically effective amount of an antagonist of a receptor on a surface of a T cell which mediates contact dependent helper effector functions, for example, an anti-gp39 antibody.Type: GrantFiled: May 18, 1998Date of Patent: December 11, 2001Assignees: Trustees of Dartmouth College, Nederlandse Organisatie Voor Teogepastnatuurwetenschappelijk Onderzoek TNOInventors: Randolph J. Noelle, Eric Claassen
-
Patent number: 6315998Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.Type: GrantFiled: February 15, 2000Date of Patent: November 13, 2001Assignee: Chiron CorporationInventors: Mark de Boer, Leah B. Conroy
-
Patent number: 6312692Abstract: A method of treating graft-vs-host diseases by administration of bone marrow and an anti-gp39 antibody specific to human gp39 is provided.Type: GrantFiled: April 30, 1998Date of Patent: November 6, 2001Assignees: Trustees of Dartmouth College, Bristol-Myers Squibb CompanyInventors: Randolph J. Noelle, Teresa M. Foy, Alejandro Aruffo, Jeffrey A. Ledbetter
-
Patent number: 6312693Abstract: The Applicants have discovered humanized anti-human CD40 antibodies which block the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.Type: GrantFiled: February 10, 1999Date of Patent: November 6, 2001Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 6306575Abstract: The present invention relates to an antibody composition which contains antibodies specific for glycophorin A, CD3, CD24, CD16, CD14, and optionally CD45RA, CD38, CD36, CD38, CD56, CD2, CD19, CD66e, CD66b, and/or antibodies specific for antigens expressed on non-hematopoietic tumor cells. A process is also provided for enriching and recovering human hematopoietic progenitor cells and stem cells in a sample containing human hematopoietic differentiated, progenitor, and stem cells, and optionally tumor cells.Type: GrantFiled: December 1, 1995Date of Patent: October 23, 2001Assignee: StemCell Technologies, Inc.Inventors: Terry Thomas, Peter Lansdorp
-
Patent number: 6297049Abstract: The present invention concerns a method of treating sepsis comprising administering a therapeutically effective amount of anti-CD14 antibody molecules. A therapeutic composition comprising anti-CD14 antibody molecules in a pharmaceutically acceptable excipient is also contemplated.Type: GrantFiled: April 3, 2000Date of Patent: October 2, 2001Assignee: The Scripps Research InstituteInventors: Richard Ulevitch, Peter Tobias, Samuel D. Wright, John C. Mathison
-
Patent number: 6274347Abstract: A shed form of leukocyte adhesion molecule-1 (LAM-1, L-selectin) is present in high levels in human plasma. Quantitative methods of detecting shed LAM-1 (sLAM-1) by Western blot and ELISA analysis are disclosed. Also disclosed are methods for the specific detection of cell-surface bound LAM-1 in the presence of shed LAM-1 and for immunotherapy using monoclonal antibodies reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1. In addition a method of producing an antibody that is reactive with cell-surface bound LAM-1 but not reactive with shed LAM-1 is disclosed.Type: GrantFiled: January 17, 1997Date of Patent: August 14, 2001Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Thomas F. Tedder, Boris Schleiffenbaum, Olivier Spertini
-
Publication number: 20010007021Abstract: The present invention relates to monoclonal antibodies (MAb) to hematopoietic facilitatory cells (FC). In particular, it relates to MAb against antigens expressed by murine FC, methods of generating the antibodies, and methods of using the same. MAb directed to markers that are expressed specifically or at higher levels by FC than by most other bone marrow cells have a wide range of applications, including but not limited to, rapid isolation of FC, identification of FC in a donor cell preparation, and molecular cloning of the genes encoding the corresponding target antigens.Type: ApplicationFiled: August 2, 1999Publication date: July 5, 2001Inventors: SUZANNE T. ILDSTAD, CHRISTINA KAUFMAN, YOLANDA COLSON